RCS - Shield Therapeutics - Abstract to be presented at Healthcare Conference

Shield TherapeuticsAnnouncement

20/10/2023 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231020:nRST8338Qa&default-theme=true

RNS Number : 8338Q  Shield Therapeutics PLC  20 October 2023

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

 Shield to Present Abstract at 26th Annual Women's Healthcare Conference 2023
on Accrufer®

 

London, UK - 20 October 2023: Shield Therapeutics plc (LSE: STX), a
commercial stage pharmaceutical company that delivers Accrufer®/Feraccru®
(ferric maltol), an innovative and differentiated specialty pharmaceutical
product, to address a significant unmet need for patients suffering from iron
deficiency (with or without anemia) reports that an abstract has been accepted
for presentation at the National Association of Nurse Practitioners in Women's
Health 26th Annual Women's Healthcare Conference taking place October 29 -
November 1 in San Diego, California. Dr Michael Cody M.D.  will present
during Monday, October 30(th) 11:45 am - 1:45 pm and Tuesday, October 31st,
11:30 am - 12:30 pm.

 

Poster title: Iron absorption is maintained over time following repeated
twice-daily ferric maltol dosing: Post hoc analysis of a multicenter,
open-label, randomized, phase 1 clinical study.

 

Poster Presentation Dates and times: Monday, October 30th; 11:45 am - 1:45 pm;
Tuesday, October 31st, 11:30 am - 12:30 pm

 

NPWH is the leading membership organization for Women's Health Nurse
Practitioners and all NPs who perform women's and gender-related healthcare.
Through continuing education, advocacy, professional development, and
research, we support our members as they strive to continuously improve access
to and quality of healthcare for women.

 

Find out more about the 26th Annual conference here National Association of
Nurse Practitioners in Women's Health (npwh.org)
(https://npwh.org/events/eventdetails.aspx?id=1647090) .

 

For further information please contact:

 

 Shield Therapeutics plc                                                                         www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                               +44 (0) 191 511 8500

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Patrick Birkholm                                                                    +44 (0)20 7418 8900

 Joint Broker

 Cavendish Capital Markets Ltd

 Geoff Nash/ George Dollemore/Nigel                                                              +44 (0)20 7220 0563
 Birks

 Financial PR & IR Advisor
 Walbrook PR
 Paul McManus/ Alice Woodings                                                                    +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 John Mullaly                                                                                    +1 617 429 3548 or jmullaly@lifesciadvisors.com

 

 

 

About Iron Deficiency and Accrufer®/Feraccru®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet
medical need for both physicians and patients.

 

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of
absorption compared to other oral iron therapies and has been shown to be an
efficacious and well-tolerated therapy in a range of clinical trials. More
information about Accrufer®/Feraccru®, including the product label, can be
found at: www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company launched
Accrufer® in the U.S. with an exclusive, multi-year collaboration agreement
with Viatris. Outside of the U.S., the Company licensed the rights to four
specialty pharmaceutical companies. Feraccru® is commercialized in the UK and
European Union by Norgine B.V. (Norgine), which also has marketing rights in
Australia and New Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and
Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma),
and with KYE Pharmaceuticals Inc. for Canada.

 

Accrufer®/Feraccru® has patent coverage until the mid-2030s.

Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPGCWUUPWGUU